TY - JOUR
T1 - Sociodemographic differences in utilization and outcomes for temporary cardiovascular mechanical support in the setting of cardiogenic shock
AU - Thangam, Manoj
AU - Luke, Alina A.
AU - Johnson, Daniel Y.
AU - Amin, Amit P.
AU - Lasala, John
AU - Huang, Kristine
AU - Joynt Maddox, Karen E.
N1 - Funding Information:
Declarations of interest/disclosures: Dr. Joynt Maddox receives research support from the National Heart, Lung, and Blood Institute (R01HL143421) and National Institute on Aging (R01AG060935), and previously did contract work for the US Department of Health and Human Services. Dr. Amit P. Amin has received funding from the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR000448, KL2TR000450, TL1TR000449), National Cancer Institute of the National Institutes of Health (1KM1CA156708-01), and an AHRQ R18 grant award (R18HS0224181-01A1). He also has unrestricted grants from Volcano corporation and MedAxiom Synergistic Healthcare Solutions Austin, TX, and is a consultant to Terumo, GE Healthcare and AstraZeneca. Dr. Lasala is a consultant for Abiomed, Abbott, Boston Scientific, Chiesi, and Gore. All other authors report no financial conflicts or relationships.
Funding Information:
This project was funded by the Smith-Oliver Research Fund, Cardiovascular Division, Department of Medicine, Washington University School of Medicine. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents. The authors acknowledge RJ Waken, Ph.D. and Daniel Y. Johnson, B.A. for their assistance with the study.
Funding Information:
Declarations of interest/disclosures: Dr. Joynt Maddox receives research support from the National Heart, Lung, and Blood Institute ( R01HL143421 ) and National Institute on Aging ( R01AG060935 ), and previously did contract work for the US Department of Health and Human Services. Dr. Amit P. Amin has received funding from the National Center for Advancing Translational Sciences of the National Institutes of Health ( UL1TR000448, KL2TR000450, TL1TR000449 ), National Cancer Institute of the National Institutes of Health ( 1KM1CA156708-01 ), and an AHRQ R18 grant award ( R18HS0224181-01A1 ). He also has unrestricted grants from Volcano corporation and MedAxiom Synergistic Healthcare Solutions Austin, TX, and is a consultant to Terumo, GE Healthcare and AstraZeneca. Dr. Lasala is a consultant for Abiomed, Abbott, Boston Scientific, Chiesi, and Gore. All other authors report no financial conflicts or relationships.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/6
Y1 - 2021/6
N2 - Background: Temporary mechanical circulatory support (MCS) devices are increasingly used in cardiogenic shock, but whether sociodemographic differences by sex, race and/or ethnicity, insurance status, and neighborhood poverty exist in the utilization of these devices is unknown. Methods: Retrospective cross-sectional study using the National Inpatient Sample for 2012-2017. Logistic regression models were used to examine predictors of use of temporary MCS devices and for in-hospital mortality, clustering by hospital-year. Results: Our study population included 109,327 admissions for cardiogenic shock. Overall, 14.3% of admissions received an intra-aortic balloon pump, 4.2% a percutaneous ventricular assist device, and 1.8% extracorporeal membranous oxygenation (ECMO). After adjusting for age, comorbidities, and hospital characteristics, use of temporary MCS was lower in women compared to men (adjusted odds ratio [aOR] = 0.76, P < .001), Black patients compared to white ones (aOR = 0.73, P < .001), those insured by Medicare (aOR = 0.75, P < .001), Medicaid (aOR = 0.74, P < .001), or uninsured (aOR = 0.90, P = .015) compared to privately insured, and those in the lowest income neighborhoods (aOR = 0.94, P = .003) versus other neighborhoods. Women, admissions covered by Medicare, Medicaid, or uninsured, and those from low-income neighborhoods also had higher mortality rates even after adjustment for MCS implantation. Conclusions: There are differences in the use of temporary MCS in the setting of cardiogenic shock among specific populations within the United States. The growing use of MCS for treating cardiogenic shock highlights the need to better understand its impact on outcomes.
AB - Background: Temporary mechanical circulatory support (MCS) devices are increasingly used in cardiogenic shock, but whether sociodemographic differences by sex, race and/or ethnicity, insurance status, and neighborhood poverty exist in the utilization of these devices is unknown. Methods: Retrospective cross-sectional study using the National Inpatient Sample for 2012-2017. Logistic regression models were used to examine predictors of use of temporary MCS devices and for in-hospital mortality, clustering by hospital-year. Results: Our study population included 109,327 admissions for cardiogenic shock. Overall, 14.3% of admissions received an intra-aortic balloon pump, 4.2% a percutaneous ventricular assist device, and 1.8% extracorporeal membranous oxygenation (ECMO). After adjusting for age, comorbidities, and hospital characteristics, use of temporary MCS was lower in women compared to men (adjusted odds ratio [aOR] = 0.76, P < .001), Black patients compared to white ones (aOR = 0.73, P < .001), those insured by Medicare (aOR = 0.75, P < .001), Medicaid (aOR = 0.74, P < .001), or uninsured (aOR = 0.90, P = .015) compared to privately insured, and those in the lowest income neighborhoods (aOR = 0.94, P = .003) versus other neighborhoods. Women, admissions covered by Medicare, Medicaid, or uninsured, and those from low-income neighborhoods also had higher mortality rates even after adjustment for MCS implantation. Conclusions: There are differences in the use of temporary MCS in the setting of cardiogenic shock among specific populations within the United States. The growing use of MCS for treating cardiogenic shock highlights the need to better understand its impact on outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85101619033&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2020.12.014
DO - 10.1016/j.ahj.2020.12.014
M3 - Article
C2 - 33359779
AN - SCOPUS:85101619033
SN - 0002-8703
VL - 236
SP - 87
EP - 96
JO - American heart journal
JF - American heart journal
ER -